Anti-hepatocyte membrane-specific lipoprotein antibody (ALSP)

ALSP is non-disease specific, and it most commonly occurs in viral and primary autoimmune hepatitis, with a lower incidence in non-hepatic patients. ALMA is one of the liver-specific antibodies. The titer of the antibody is in a parallel relationship with the degree of loss of liver function. ALSP is usually determined by indirect immunofluorescence and ELIASA. The principle of indirect immunofluorescence experiments is to label fluorescein on the corresponding antibody and directly react with the corresponding antigen. In the first step, an unknown unlabeled antibody (sample to be tested) is added to a known antigen sample, and incubated at 37 ° C for 30 min in a wet box to sufficiently bind the antigen antibody, followed by washing to remove unbound antibody. In the second step, a fluorescently labeled anti-globulin antibody or an anti-IgG, IgM antibody is added. If an antigen-antibody reaction occurs in the first step, the labeled anti-globulin antibody will further bind to the antigen-bound antibody, thereby identifying an unknown antibody. ELISA is a highly sensitive test technique that combines the specific reaction of antigens and antibodies with the efficient catalysis of enzymes on substrates based on immunological reactions. The reaction of the antigen and the antibody is carried out in a well of a solid phase carrier, a polystyrene microtiter plate, and after each reagent is added, the excess free reactant can be removed by washing to ensure the specificity of the test result. stability. Basic Information Specialist classification: Digestive examination classification: immune examination Applicable gender: whether men and women apply fasting: not fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: Prompt for the presence of hepatitis. Tips: The ratio of the absorbance (A) ratio (P/N) of the serum to the negative control to be tested is normal. Indirect immunofluorescence and ELISA were negative. Clinical significance Positive: Active period of autoimmune hepatitis (positive rate 50~100%), acute viral hepatitis (positive rate 11~93%), chronic viral hepatitis B (positive rate 28~93%), chronic viral hepatitis C (positive rate) 0~10%), occult cirrhosis (positive rate 0~36%), other liver diseases (positive rate 0~27%), other liver diseases (positive rate 0~17%), non-hepatic autoimmune disease (positive rate) 0~18%). Precautions (1) According to the survey of normal population, the mean of serum radioactivity (cpm) plus 2 standard deviation is the upper limit of normal (radioimmunoassay). (2) The ratio of absorbance (A) of the test serum to the negative control (P/N) < 2.1 (ELISA method). Inspection process Same as radioimmunoassay. Not suitable for the crowd There are no taboos. Adverse reactions and risks There are no related complications and hazards.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.